GO:2001306 lipoxin B4 biosynthetic process: Anti-Inflammatory Lipid Mediator Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001306 (lipoxin B4 biosynthetic process) describes the enzymatic formation of lipoxin B4 (LXB4), a C20 hydroxy fatty acid with (5S)-, (14R)- and (15S)-hydroxy groups and (6E)-, (8Z)-, (10E)- and (12E)-double bonds.
• Lipoxins, including LXB4, are eicosanoids that carry intra- and intercellular messages and are recognized for their anti-inflammatory and pro-resolving actions.
• LXB4 biosynthesis is part of specialized pro-resolving mediator (SPM) biology, a lipid class measurable in inflammatory-resolution transitions in vivo.
• LXB4 promotes resolution of allergic inflammation in the upper and lower airways of mice, supporting its role as a pro-resolving mediator.
• Lipoxin B4 mitigates TRPV4-activated Müller cell gliosis during ocular hypertension, linking this pathway to retinal neuroinflammatory disease.
• Analytical advances such as positive-ion LC/ESI-MS/MS of polyunsaturated fatty acids with allylic vicinal diols support structural characterization of lipoxins and related mediators.
Description
GO:2001306, lipoxin B4 biosynthetic process, is a biological_process term in the Gene Ontology that covers the chemical reactions and pathways resulting in the formation of lipoxin B4 (LXB4). LXB4 is a C20 hydroxy fatty acid carrying (5S)-, (14R)- and (15S)-hydroxy groups together with (6E)-, (8Z)-, (10E)- and (12E)-double bonds, a structure that places it within the lipoxin family of eicosanoids. Lipoxins were among the first recognized eicosanoids shown to carry intra- and intercellular messages, distinguishing them from classical pro-inflammatory lipid mediators. For researchers, GO:2001306 matters because lipoxin B4 is not merely a metabolic end-product but a bioactive mediator with anti-inflammatory and pro-resolving functions. Lipoxin B4 promotes the resolution of allergic inflammation in the upper and lower airways of mice, demonstrating a functional role in terminating inflammatory responses. In the eye, lipoxin B4 mitigates TRPV4-activated Müller cell gliosis during ocular hypertension, connecting this biosynthetic pathway to retinal stress responses. Lipidomic studies further position lipoxin B4 among signature inflammatory and specialized pro-resolving mediators at the junction of inflammation-resolution transition in mouse lungs exposed to multiwalled carbon nanotubes. Because LXB4 is a lipid rather than a protein, the biosynthetic process is best studied through the enzymes, substrates and analytical workflows that generate and detect it. Early work showed that lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils, revealing a dissociation between lipid remodeling and adhesion. Modern mass spectrometry methods for polyunsaturated fatty acids with allylic vicinal diols provide the structural evidence needed to confirm LXB4 formation. Together, these findings make GO:2001306 a compact, testable ontology node for studies of resolution biology, airway disease, ocular neuroinflammation and lipid mediator analytics.
lipoxin B4 biosynthetic process At A Glance
| GO ID | GO:2001306 |
|---|---|
| GO term | lipoxin B4 biosynthetic process |
| Ontology | biological_process |
| Synonym | LXB4 biosynthesis; LXB4 formation; lipoxin B4 synthesis; lipoxin B4 anabolism |
| Major function | Enzymatic formation of the pro-resolving lipid mediator lipoxin B4 |
| Chemical product | Lipoxin B4, a C20 hydroxy fatty acid with (5S)-, (14R)- and (15S)-hydroxy groups and (6E)-, (8Z)-, (10E)- and (12E)-double bonds |
| Pathway context | Lipoxin and specialized pro-resolving mediator (SPM) biosynthesis |
| Representative bioactivity | Promotes resolution of allergic airway inflammation in mice |
| Disease relevance | Ocular hypertension-associated Müller cell gliosis; inflammatory-resolution imbalance in lung injury models |
What Is GO:2001306?
In plain terms, GO:2001306 describes the set of enzymatic reactions and pathways that build lipoxin B4. According to the QuickGO definition, it is the chemical reactions and pathways resulting in the formation of lipoxin B4, a C20 hydroxy fatty acid having (5S)-, (14R)- and (15S)-hydroxy groups as well as (6E)-, (8Z)-, (10E)- and (12E)-double bonds. The term belongs to the biological_process aspect of the Gene Ontology and is synonymous with lipoxin B4 biosynthesis, LXB4 biosynthesis, LXB4 formation and related phrases. It should not be confused with the biosynthesis of other lipoxins or other specialized pro-resolving mediators; its scope is specifically the formation of LXB4.
Why Is lipoxin B4 biosynthetic process Important in Cell Biology?
GO:2001306 is important because it defines the biosynthetic route to a lipid mediator whose biological output is the active termination of inflammation rather than its initiation. Lipoxin B4 promotes the resolution of allergic inflammation in the upper and lower airways of mice, so the pathway is directly relevant to asthma and allergic airway disease research. In the retina, lipoxin B4 mitigates TRPV4-activated Müller cell gliosis during ocular hypertension, linking the pathway to neuroinflammatory and gliotic processes in the eye. Lipidomic profiling identifies lipoxin B4 among signature mediators at the inflammation-resolution transition in lungs exposed to multiwalled carbon nanotubes, showing that the pathway is engaged in real exposure models. Because lipoxins were early recognized as eicosanoids carrying intra- and intercellular messages, the pathway also serves as a paradigm for intercellular lipid signaling. Finally, the pathway is analytically demanding, and advances in mass spectrometry of polyunsaturated fatty acids with allylic vicinal diols are essential for rigorous detection and structural confirmation of LXB4.
• Defines the biosynthetic origin of a pro-resolving lipid mediator rather than a pro-inflammatory one.
• Provides a mechanistic framework for resolution of allergic airway inflammation in mice.
• Links lipid mediator biosynthesis to retinal Müller cell gliosis under ocular hypertension.
• Supports lipidomic monitoring of inflammation-resolution transitions in lung exposure models.
• Connects to eicosanoid cell-cell communication and neutrophil lipid remodeling.
• Requires specialized mass spectrometry for structural confirmation of allylic vicinal diol-containing fatty acids.
• Offers a target concept for anti-inflammatory and immunomodulatory strategies involving lipoxins and synthetic analogs.
• Helps distinguish LXB4 biosynthesis from other lipoxin and SPM biosynthetic routes in ontology-based analyses.
What Happens During lipoxin B4 biosynthetic process?
Substrate supply and arachidonic acid mobilization
In simple terms: The pathway needs fatty acid building blocks to be made available before lipoxin B4 can be assembled.
Lipoxin B4 is a C20 hydroxy fatty acid, so its biosynthesis depends on the availability of C20 polyunsaturated fatty acid precursors. Studies in human neutrophils showed that lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid, indicating that lipoxin exposure can influence lipid remodeling and precursor mobilization without directly driving oxygenation in that setting. This dissociation between lipid remodeling and adhesion highlights that substrate supply and downstream enzymatic conversion are separable regulatory layers within lipoxin biology. In practical terms, the biosynthetic process begins with precursor availability and the cellular context that determines whether that precursor is converted toward LXB4.
Enzymatic conversion to the lipoxin B4 structure
In simple terms: Enzymes chemically modify the fatty acid precursor to install the specific hydroxyl groups and double bonds that define lipoxin B4.
The defining outcome of GO:2001306 is the formation of lipoxin B4, a C20 hydroxy fatty acid having (5S)-, (14R)- and (15S)-hydroxy groups as well as (6E)-, (8Z)-, (10E)- and (12E)-double bonds. This precise stereochemistry and double-bond geometry distinguishes LXB4 from other lipoxins and from related eicosanoids, and it is the structural criterion by which the biosynthetic process is recognized. Lipoxins as a class are eicosanoids that carry intra- and intercellular messages, meaning the enzymatic conversion step is embedded in cell-cell communication rather than occurring in isolation. The biosynthetic process therefore represents a coordinated sequence of transformations that installs the hydroxyl and double-bond pattern characteristic of LXB4.
Lipoxin B4 as a pro-resolving mediator output
In simple terms: Once made, lipoxin B4 acts as a signal that helps inflammation resolve rather than persist.
The functional output of the biosynthetic process is a mediator with anti-inflammatory and pro-resolving actions. Lipoxin B4 promotes the resolution of allergic inflammation in the upper and lower airways of mice, demonstrating that the product of GO:2001306 has measurable pro-resolving activity in vivo. Lipidomic analysis of mouse lungs exposed to multiwalled carbon nanotubes identified signature inflammatory and specialized pro-resolving mediators at the junction of the inflammation-resolution transition, a context in which lipoxin B4 is measured as part of the SPM response. These findings indicate that the biosynthetic process is functionally coupled to the active termination of inflammation.
Detection and structural confirmation of the product
In simple terms: Because lipoxin B4 is a lipid, specialized analytical chemistry is needed to prove it was actually made.
Confirming that GO:2001306 has occurred requires analytical evidence of the LXB4 structure, including its hydroxylation pattern and double-bond geometry. Characteristic fragmentation of polyunsaturated fatty acids with allylic vicinal diols in positive-ion LC/ESI-MS/MS provides a mass spectrometry framework relevant to the structural characterization of such lipid mediators. Lipidomic workflows have been applied to detect signature inflammatory and specialized pro-resolving mediators, including lipoxin B4, in biological samples such as mouse lungs. Together, these methods allow researchers to connect enzymatic activity to the presence of the correctly structured LXB4 product.
Cellular and tissue contexts of LXB4 formation
In simple terms: Lipoxin B4 biosynthesis happens in specific cells and tissues, which shapes how the pathway is studied.
Human neutrophils have been used to study lipoxin A4 and lipoxin B4 effects on arachidonic acid release and oxygenation, establishing leukocytes as a relevant cellular context for lipoxin biology. In the eye, lipoxin B4 mitigates TRPV4-activated Müller cell gliosis during ocular hypertension, implicating retinal Müller cells and TRPV4-related signaling in the biological impact of this mediator. In the airways, lipoxin B4 promotes resolution of allergic inflammation in the upper and lower airways of mice, defining a tissue context in which the biosynthetic product exerts pro-resolving effects. These cellular and tissue settings provide the experimental systems in which GO:2001306 is most often investigated.
Key Genes Involved in GO:2001306 lipoxin B4 biosynthetic process
Because lipoxin B4 is a lipid mediator rather than a protein, the genes and proteins most relevant to GO:2001306 are the enzymes, receptors and signaling components that govern lipoxin biosynthesis, detection and pro-resolving activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALOX5 | Lipoxygenase family enzyme implicated in lipoxin-type eicosanoid formation | Studied in the context of lipoxin biosynthesis and eicosanoid signaling |
| ALOX5AP | Accessory protein supporting lipoxygenase activity in leukocytes | Relevant to leukocyte lipoxin and eicosanoid production |
| ALOX12 | Lipoxygenase family enzyme contributing to lipoxin pathway reactions | Considered in lipoxin biosynthetic routes |
| ALOX15 | Lipoxygenase family enzyme contributing to lipoxin and SPM formation | Studied in specialized pro-resolving mediator biosynthesis |
| PTGS2 | Cyclooxygenase enzyme relevant to eicosanoid and lipoxin pathway context | Used to contextualize lipoxin formation within eicosanoid networks |
| TRPV4 | Ion channel linked to Müller cell gliosis that lipoxin B4 mitigates | Directly implicated in ocular hypertension gliosis studies |
| GFAP | Glial activation marker associated with Müller cell gliosis | Used to assess gliotic responses modulated by lipoxin B4 |
| IL4 | Type 2 cytokine central to allergic airway inflammation | Relevant to allergic inflammation models in which LXB4 promotes resolution |
| IL5 | Type 2 cytokine driving eosinophilic airway inflammation | Measured in allergic airway resolution studies with LXB4 |
| IL13 | Type 2 cytokine promoting airway remodeling and mucus responses | Evaluated in allergic inflammation resolution experiments |
| CCL11 | Eosinophil-recruiting chemokine in allergic inflammation | Used as an inflammatory readout in LXB4 airway studies |
| FPR2 | Formyl peptide receptor family member associated with lipoxin signaling | Studied in lipoxin and synthetic analog immunomodulation |
| GPR32 | Receptor associated with pro-resolving lipid mediator signaling | Relevant to lipoxin and SPM receptor biology |
| NFKB1 | Transcription factor controlling inflammatory gene expression | Used to assess anti-inflammatory effects of lipoxins and analogs |
| TNF | Pro-inflammatory cytokine counter-regulated by pro-resolving mediators | Measured in inflammation-resolution studies involving lipoxins |
| IL6 | Pro-inflammatory cytokine modulated during resolution | Assessed in SPM and lipoxin-related inflammation models |
| PTGS1 | Cyclooxygenase enzyme contributing to eicosanoid pathway context | Used to frame lipoxin biosynthesis within eicosanoid metabolism |
| NLRP3 | Inflammasome component linked to inflammatory signaling | Relevant to anti-inflammatory actions attributed to lipoxins |
How Is lipoxin B4 biosynthetic process Regulated?
Regulation of lipoxin B4 biosynthetic process operates at the level of substrate availability, enzymatic conversion and cellular context rather than through a single dedicated transcription factor. Lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils, indicating that precursor mobilization can be uncoupled from oxygenation and that lipid remodeling and adhesion are dissociable regulatory events. Lipoxins as a class function as eicosanoids carrying intra- and intercellular messages, so their production is influenced by cell-cell communication and the presence of appropriate biosynthetic enzyme complements in interacting cells. The biological impact of the product is further regulated by receptor-level and downstream signaling events, as shown by the anti-inflammatory and immunomodulatory actions of lipoxins and synthetic lipoxin analogs. In disease contexts, the pathway is engaged during inflammation-resolution transitions, as demonstrated by lipidomic detection of signature inflammatory and specialized pro-resolving mediators in mouse lungs exposed to multiwalled carbon nanotubes. In the eye, TRPV4-activated Müller cell gliosis during ocular hypertension is mitigated by lipoxin B4, indicating that stress-responsive signaling pathways can modulate the consequences of this mediator.
lipoxin B4 biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRPV4 | Ocular hypertension-associated Müller cell gliosis | Retinal Müller cell lines or ocular hypertension mouse models with LXB4 treatment |
| GFAP | Glial activation and retinal stress responses | Immunostaining and gliosis marker assays in retinal tissue |
| IL4 / IL5 / IL13 | Allergic airway inflammation and resolution | Murine allergic airway models with LXB4 administration |
| CCL11 | Eosinophilic inflammation in airways | Airway inflammation models with eosinophil recruitment readouts |
| TNF / IL6 | Inflammation-resolution imbalance in lung exposure | Nanotube-exposed mouse lung lipidomic and cytokine studies |
Allergic airway inflammation and asthma
Lipoxin B4 promotes the resolution of allergic inflammation in the upper and lower airways of mice, establishing the biosynthetic pathway as relevant to allergic airway disease biology. Because the product of GO:2001306 drives resolution rather than initiation of inflammation, defects or imbalances in LXB4 formation could contribute to persistent allergic inflammation. Lipoxins and synthetic lipoxin analogs have been reviewed for their anti-inflammatory functions and immunomodulatory potential, supporting interest in this pathway for airway disease research.
Ocular hypertension and retinal gliosis
Lipoxin B4 mitigates TRPV4-activated Müller cell gliosis during ocular hypertension, linking GO:2001306 to retinal neuroinflammatory and gliotic responses. Müller cell gliosis is a reactive response of retinal glia, and the ability of LXB4 to mitigate this process suggests that the biosynthetic pathway may be protective in ocular hypertensive settings. This connection makes the pathway a candidate area for studies of retinal stress and glial activation.
Lung injury and inflammation-resolution imbalance
Lipidomic analysis of mouse lungs exposed to multiwalled carbon nanotubes revealed signature inflammatory and specialized pro-resolving mediators at the junction of the inflammation-resolution transition, a setting in which lipoxin B4 is among the measured mediators. This positions GO:2001306 within exposure-related lung inflammation research, where the balance between pro-inflammatory and pro-resolving lipids is a central question. The presence of LXB4 at the resolution transition supports its use as a biomarker concept in resolution biology.
Eicosanoid signaling and immunomodulation
Lipoxins were recognized early as eicosanoids carrying intra- and intercellular messages, and lipoxin and synthetic lipoxin analogs have been reviewed for anti-inflammatory functions and new concepts in immunomodulation. Human neutrophil studies showing that lipoxin A4 and lipoxin B4 stimulate arachidonic acid release without oxygenation connect the pathway to leukocyte lipid remodeling and adhesion biology. These findings support the broader relevance of GO:2001306 to immunomodulatory research beyond any single organ system.
From lipoxin B4 biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate biosynthetic enzyme reduce LXB4 formation? | Knockout cell model with lipidomic detection of LXB4 |
| Does a specific catalytic residue control LXB4 stereochemistry? | Point-mutation knock-in of the candidate enzyme followed by LC/ESI-MS/MS |
| Can a tagged enzyme be used to track LXB4 biosynthetic complexes? | Tagged knock-in for affinity purification and imaging |
| Does overexpression of a candidate enzyme increase LXB4 output? | Overexpression cell model with targeted lipidomics |
| Does LXB4 mitigate gliosis in retinal cells? | Müller cell model with TRPV4 activation and LXB4 treatment |
| Does LXB4 promote resolution in allergic airways? | Murine allergic airway inflammation model with LXB4 administration |
How to Study the lipoxin B4 biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC/ESI-MS/MS | Structural features and abundance of lipoxin-type lipids | Confirming LXB4 formation and structure |
| Targeted lipidomics | Levels of inflammatory and pro-resolving mediators | Detecting LXB4 at inflammation-resolution transitions |
| Arachidonic acid release assay | Precursor mobilization from cells | Dissecting lipid remodeling from oxygenation in neutrophils |
| Allergic airway inflammation model | Resolution of airway inflammation | Testing pro-resolving effects of LXB4 in mice |
| Ocular hypertension model | Müller cell gliosis and retinal stress | Evaluating LXB4 effects on TRPV4-activated gliosis |
| Cytokine profiling | Inflammatory mediator output | Assessing immunomodulatory effects of lipoxins and analogs |
| Receptor signaling assays | Downstream signaling responses to lipoxins | Studying lipoxin and SPM receptor biology |
| Immunostaining for glial markers | Glial activation state in tissue | Quantifying gliosis modulation by LXB4 |
Targeted lipidomics and LC/ESI-MS/MS
Because GO:2001306 produces a lipid product, targeted lipidomics is the primary readout. Positive-ion LC/ESI-MS/MS with characteristic fragmentation of polyunsaturated fatty acids bearing allylic vicinal diols supports structural characterization of lipoxin-type mediators. Lipidomic profiling has been used to detect signature inflammatory and specialized pro-resolving mediators, including lipoxin B4, in mouse lungs exposed to multiwalled carbon nanotubes. These workflows allow researchers to quantify LXB4 and related mediators across experimental conditions.
Cell-based assays of precursor release and remodeling
Human neutrophil studies provide a cell-based framework for measuring arachidonic acid release and oxygenation in response to lipoxin A4 and lipoxin B4. Such assays can dissect lipid remodeling from adhesion and oxygenation events, which is important for understanding how the biosynthetic process is regulated. Cell-based systems also allow testing of whether candidate enzymes or receptors alter LXB4 formation or response.
In vivo inflammation-resolution models
Murine allergic airway inflammation models have been used to show that lipoxin B4 promotes resolution in the upper and lower airways. Lung exposure models combined with lipidomics allow measurement of LXB4 at the inflammation-resolution transition. Ocular hypertension models with Müller cell gliosis readouts connect the pathway to retinal stress biology. Together, these in vivo systems test the functional consequences of altering LXB4 biosynthesis.
Receptor and signaling readouts
Lipoxins and synthetic lipoxin analogs have been reviewed for anti-inflammatory functions and immunomodulation, providing a framework for receptor and signaling readouts. Lipoxins act as eicosanoids carrying intra- and intercellular messages, so signaling assays should consider both autocrine and paracrine effects. Measuring downstream inflammatory transcription factors and cytokines helps connect LXB4 formation to functional outcomes.
How CRISPR Can Be Used to Study GO:2001306 lipoxin B4 biosynthetic process
Knockout
Knockout models are used to test whether a candidate enzyme is required for lipoxin B4 formation. Because GO:2001306 is defined by the production of a specific lipid product, knockout cells can be profiled by targeted lipidomics to determine whether LXB4 levels fall when the candidate gene is disrupted. Such experiments help distinguish enzymes that are essential for LXB4 biosynthesis from those that contribute to broader eicosanoid networks.
Point Mutation
Point-mutation models allow interrogation of catalytic residues and stereochemical control. Since lipoxin B4 is defined by specific (5S)-, (14R)- and (15S)-hydroxy groups and defined double-bond geometry, subtle changes in enzyme active sites could alter product structure. Positive-ion LC/ESI-MS/MS with characteristic fragmentation of allylic vicinal diols can be used to verify whether point mutations change the LXB4 product profile.
Knock-in
Knock-in strategies, including tagged knock-in, enable tracking of biosynthetic enzymes and their complexes. Tagged enzymes can be affinity-purified to identify interaction partners relevant to lipoxin biosynthesis and intercellular signaling. Knock-in reporters can also be used to monitor pathway activity in specific cell types such as leukocytes or retinal Müller cells.
Overexpression
Overexpression models test whether increasing a candidate enzyme raises LXB4 output. Because the pathway product is a measurable lipid, overexpression cells can be analyzed by targeted lipidomics to quantify changes in LXB4 and related specialized pro-resolving mediators. Overexpression can also be combined with inflammation-resolution assays to test whether increased LXB4 formation enhances pro-resolving activity.
How EDITGENE Supports lipoxin B4 biosynthetic process Research
Researchers studying lipoxin B4 biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in LXB4 formation or in the cellular response to this mediator. Because the pathway output is a structurally defined lipid, causal claims require both genetic perturbation and rigorous lipid detection. EDITGENE provides the CRISPR cell models and analytical support needed to connect genotype to LXB4 biosynthesis and function.
Contact EDITGENE today to design your custom CRISPR model for lipoxin B4 biosynthetic process research.
Frequently Asked Questions About lipoxin B4 biosynthetic process
What is lipoxin B4 biosynthetic process?
It is the biological process defined by GO:2001306, covering the chemical reactions and pathways resulting in the formation of lipoxin B4, a C20 hydroxy fatty acid with (5S)-, (14R)- and (15S)-hydroxy groups and (6E)-, (8Z)-, (10E)- and (12E)-double bonds.
What is the GO ID for lipoxin B4 biosynthetic process?
The Gene Ontology identifier is GO:2001306, and the term belongs to the biological_process aspect.
What genes are involved in lipoxin B4 biosynthetic process?
Lipoxin biosynthesis involves lipoxygenase-family enzymes and related eicosanoid pathway components, and the biological effects of the product involve receptors and signaling genes such as TRPV4 in retinal gliosis and type 2 cytokines in allergic airway models.
What does lipoxin B4 do in the body?
Lipoxin B4 is a pro-resolving mediator that promotes the resolution of allergic inflammation in the upper and lower airways of mice and mitigates TRPV4-activated Müller cell gliosis during ocular hypertension.
How is lipoxin B4 detected experimentally?
Lipoxin B4 is typically detected by targeted lipidomics and mass spectrometry, including positive-ion LC/ESI-MS/MS methods developed for polyunsaturated fatty acids with allylic vicinal diols.
Is lipoxin B4 the same as lipoxin A4?
No. Lipoxin B4 is a distinct C20 hydroxy fatty acid with its own hydroxylation pattern and double-bond geometry, and it is covered by the separate GO term GO:2001306. Both lipoxins have been studied together in neutrophil lipid remodeling experiments.
Why are lipoxins important in inflammation?
Lipoxins are eicosanoids that carry intra- and intercellular messages and have anti-inflammatory and pro-resolving functions, making them central to resolution biology.
Can CRISPR be used to study lipoxin B4 biosynthesis?
Yes. Knockout, point-mutation, knock-in and overexpression models can be combined with targeted lipidomics to test whether candidate genes are required for or sufficient to drive LXB4 formation.
What diseases are linked to lipoxin B4 biosynthetic process?
Research links this pathway to allergic airway inflammation, ocular hypertension-associated retinal gliosis and inflammation-resolution imbalance in lung exposure models.
What model systems are used to study lipoxin B4?
Common systems include human neutrophil assays, murine allergic airway inflammation models, ocular hypertension models and lipidomic analysis of exposed mouse lungs.
Conclusion
GO:2001306, lipoxin B4 biosynthetic process, defines the enzymatic formation of a structurally precise pro-resolving lipid mediator with demonstrated anti-inflammatory actions in allergic airway and ocular models. Because the pathway product is a lipid, progress depends on combining genetic perturbation with rigorous lipidomic and mass spectrometric detection. Researchers studying this pathway can use CRISPR knockout, point-mutation, knock-in and overexpression models to establish causal links between candidate genes and LXB4 formation, then validate functional consequences in inflammation-resolution systems.
References
- 1. Kumar M et al.. 2026. Lipoxin B4 Mitigates TRPV4-Activated Müller Cell Gliosis During Ocular Hypertension.. Invest Ophthalmol Vis Sci 67(2):2 PMID: 41626873
- 2. Rokach J et al.. 1988. The lipoxins.. Int J Biochem 20(8):753-8 PMID: 3139479
- 3. Serhan CN. 1991. Lipoxins: eicosanoids carrying intra- and intercellular messages.. J Bioenerg Biomembr 23(1):105-22 PMID: 2010431
- 4. Nigam S et al.. 1990. Lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils: dissociation between lipid remodeling and adhesion.. J Cell Physiol 143(3):512-23 PMID: 2162850
- 5. Ma Q et al.. 2026. Lipidomics analysis reveals signature inflammatory and specialized pro-resolving mediators at the junction of inflammation-resolution transition in mouse lungs exposed to multiwalled carbon nanotubes.. Nanotoxicology 20(1-2):1-17 PMID: 41505901
- 6. Zhu H et al.. 2023. Characteristic fragmentation of polyunsaturated fatty acids with allylic vicinal diols in positive-ion LC/ESI-MS/MS.. J Lipid Res 64(6):100384 PMID: 37172692
- 7. Karra L et al.. 2015. Lipoxin B₄ promotes the resolution of allergic inflammation in the upper and lower airways of mice.. Mucosal Immunol 8(4):852-62 PMID: 25465102
- 8. Parkinson JF. 2006. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation.. Inflamm Allergy Drug Targets 5(2):91-106 PMID: 16613568
